RESOURCES

Check out our resource library!

PUBLICATIONS AND POSTERS


Telix Pharmaceuticals Limited is proud to share our resource library of publications, posters and presentations about our investigational pipeline candidates.

December 2021 – TRALA Study of TLX66 in AL-Amyloidosis presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

Autologous Stem Cell Transplantation in AL-Amyloidosis following Yttrium-90 Labelled Anti-CD66 Monoclonal Antibody as Sole Conditioning is Associated with Low Toxicity and Demonstrable Disease Responses

Authors: Kim H. Orchard MBBS PhD1; Jon Langford MSc SRPharms2; Matthew GuyPhD3; Sofia Michopoulou PhD3; Gemma Lewis MPhys3; Julian Williams4; Clint Zvavamwe MSc5; Claire Hutchison BSc1; Jane Nunnick6; Amanda Blackwell SRN1; Pei-San Chan MSc7; Casper Wickham MSc8; Ann-Marie Quigley MD9; Mark Cook MBChB PhD6; Graham Jackson MD10; Philip Hawkins MD PhD11, Ashu Wechalekar MD11

1Wessex Blood and Marrow Transplant & Cell Therapy Program, Department of Haematology and BMT, University Hospital Southampton and Targeted Radiotherapy Group, University of Southampton UK; 2Targeted Radiotherapy Group, University of Southampton UK; 3Department of Medical Physics, University Hospital Southampton; 4Department of Nuclear Medicine, University Hospital Southampton; 5Radiopharmacy, University Hospital Southampton; 6Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham UK; 7Radiopharmacy, Royal Free Hospital, London UK; 8Department of Medical Physics, Royal Free Hospital, London UK; 9Department of Nuclear Medicine, Royal Free Hospital, London UK; 10Department of Haematology, Freeman Hospital, Newcastle upon Tyne Hospitals, Newcastle UK; 11National Amyloidosis Centre, University College London (Royal Free Campus), London UK

To view a video of Dr. Kim Orchard presenting the study at ASH, please click here. 

To download the PDF please click here.

November 2021 – International Kidney Cancer Symposium (IKCS) 2021 

ZIRCON: TLX250-CDx, Multi-Center Phase III Trial for PET/CT Imaging of Clear Cell Kidney Cancer

Authors: Brian Shuch1, Allan Pantuck 1, and Colin Hayward2

1Department of Urology, University of California at Los Angeles, Los Angeles, CA; Telix Pharmaceuticals, Melbourne, Australia

To download the PDF please click here.

October 2021 – Congress of Neurological Surgeons (CNS) Meeting | Late-Breaking Oral Presentation

IPAX-1: PHASE 1/2 STUDY OF 4-L-[131I] IODO-PHENYLALANINE (131I-IPA) COMBINED WITH EXTERNAL RADIATION THERAPY (XRT) AS TREATMENT FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME

Authors: Josef Pichler1, Colin Hayward2, Mary Jessel2

1Kepler University Hospital, Linz, Austria; 2Telix Pharmaceuticals, Melbourne, Australia

To download the PDF please click here.

21 May 2021 – Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting

The ZIRCON Study: A Phase III diagnostic study for patients with an indeterminate renal mass with planned surgery.

Authors: K. Vadali, T. Brown, D. Meyrick, S. Gribble, C. Hayward, C. Krenus, J. Arora

Telix Pharmaceuticals Ltd., Australia, and USA

To download PDF please click here.

21 May 2021 – Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting

89Zr-DFO-girentuximab (TLX250-CDx) as a CAIX targeting radiotracer for positron emission tomography

Authors: Lenzo, N.i, Quan-Lee, B.i, La Bianca, Sii., Meyrick, D.iii

iGenesisCare Oncology, Sydney, NSW, Australia; iiPerth Urology Clinic, Murdoch WA, Australia; iiiTelix Pharmaceuticals, Melbourne, VIC, Australia

To download PDF please click here.

May 2020 – American Society of Clinical Oncology (ASCO) | Central Nervous System Tumors

IPAX-1: PHASE 1/2 STUDY OF 4-L-[131I] IODO-PHENYLALANINE (131I-IPA) COMBINED WITH EXTERNAL RADIATION THERAPY (XRT) AS TREATMENT FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME

Authors: Josef Pichler1, Rosalind Wilson2
1Kepler University Hospital, Linz, Austria; 2Telix Pharmaceuticals, Melbourne, Australia.

To download PDF please click here.